The history and mystery of sacubitril/valsartan: From clinical trial to the real world
Heart failure is a serious threat to human health, with morbidity and mortality rates increasing despite the existence of multiple treatment options. Therefore, it is necessary to identify new therapeutic targets for this disease. Sacubitril/valsartan is a supramolecular sodium salt complex of the e...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2023-03-01
|
| Series: | Frontiers in Cardiovascular Medicine |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fcvm.2023.1102521/full |
| _version_ | 1797858953386786816 |
|---|---|
| author | Mingsong Zhang Yifei Zou Yangxue Li He Wang Wei Sun Bin Liu |
| author_facet | Mingsong Zhang Yifei Zou Yangxue Li He Wang Wei Sun Bin Liu |
| author_sort | Mingsong Zhang |
| collection | DOAJ |
| description | Heart failure is a serious threat to human health, with morbidity and mortality rates increasing despite the existence of multiple treatment options. Therefore, it is necessary to identify new therapeutic targets for this disease. Sacubitril/valsartan is a supramolecular sodium salt complex of the enkephalinase inhibitor prodrug sacubitril and the angiotensin receptor blocker valsartan. Its combined action increases endogenous natriuretic peptides while inhibiting the renin-angiotensin-aldosterone system and exerting cardioprotective effects. Clinical evidence suggests that sacubitril/valsartan is superior to conventional renin-angiotensin-aldosterone inhibitor therapy for patients with reduced ejection fraction heart failure who can tolerate angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers. The therapy reduces the risk of heart failure hospitalization, cardiovascular mortality, and all-cause mortality and has a better safety and tolerability record. This review describes the potential pathophysiological mechanisms of cardiomyocyte injury amelioration by sacubitril/valsartan. We explore the protective effects of sacubitril/valsartan and outline the therapeutic value in patients with heart failure by summarizing the results of recent large clinical trials. Furthermore, a preliminary outlook shows that sacubitril/valsartan may be effective at treating other diseases, and provides some exploratory observations that lay the foundation for future studies on this drug. |
| first_indexed | 2024-04-09T21:21:42Z |
| format | Article |
| id | doaj.art-8876c8f2d3104da3ab9c8dd913fa71a4 |
| institution | Directory Open Access Journal |
| issn | 2297-055X |
| language | English |
| last_indexed | 2024-04-09T21:21:42Z |
| publishDate | 2023-03-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Cardiovascular Medicine |
| spelling | doaj.art-8876c8f2d3104da3ab9c8dd913fa71a42023-03-28T05:00:25ZengFrontiers Media S.A.Frontiers in Cardiovascular Medicine2297-055X2023-03-011010.3389/fcvm.2023.11025211102521The history and mystery of sacubitril/valsartan: From clinical trial to the real worldMingsong ZhangYifei ZouYangxue LiHe WangWei SunBin LiuHeart failure is a serious threat to human health, with morbidity and mortality rates increasing despite the existence of multiple treatment options. Therefore, it is necessary to identify new therapeutic targets for this disease. Sacubitril/valsartan is a supramolecular sodium salt complex of the enkephalinase inhibitor prodrug sacubitril and the angiotensin receptor blocker valsartan. Its combined action increases endogenous natriuretic peptides while inhibiting the renin-angiotensin-aldosterone system and exerting cardioprotective effects. Clinical evidence suggests that sacubitril/valsartan is superior to conventional renin-angiotensin-aldosterone inhibitor therapy for patients with reduced ejection fraction heart failure who can tolerate angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers. The therapy reduces the risk of heart failure hospitalization, cardiovascular mortality, and all-cause mortality and has a better safety and tolerability record. This review describes the potential pathophysiological mechanisms of cardiomyocyte injury amelioration by sacubitril/valsartan. We explore the protective effects of sacubitril/valsartan and outline the therapeutic value in patients with heart failure by summarizing the results of recent large clinical trials. Furthermore, a preliminary outlook shows that sacubitril/valsartan may be effective at treating other diseases, and provides some exploratory observations that lay the foundation for future studies on this drug.https://www.frontiersin.org/articles/10.3389/fcvm.2023.1102521/fullheart failuresacubitril/valsartancardiovascularclinical applicationbasic medical research |
| spellingShingle | Mingsong Zhang Yifei Zou Yangxue Li He Wang Wei Sun Bin Liu The history and mystery of sacubitril/valsartan: From clinical trial to the real world Frontiers in Cardiovascular Medicine heart failure sacubitril/valsartan cardiovascular clinical application basic medical research |
| title | The history and mystery of sacubitril/valsartan: From clinical trial to the real world |
| title_full | The history and mystery of sacubitril/valsartan: From clinical trial to the real world |
| title_fullStr | The history and mystery of sacubitril/valsartan: From clinical trial to the real world |
| title_full_unstemmed | The history and mystery of sacubitril/valsartan: From clinical trial to the real world |
| title_short | The history and mystery of sacubitril/valsartan: From clinical trial to the real world |
| title_sort | history and mystery of sacubitril valsartan from clinical trial to the real world |
| topic | heart failure sacubitril/valsartan cardiovascular clinical application basic medical research |
| url | https://www.frontiersin.org/articles/10.3389/fcvm.2023.1102521/full |
| work_keys_str_mv | AT mingsongzhang thehistoryandmysteryofsacubitrilvalsartanfromclinicaltrialtotherealworld AT yifeizou thehistoryandmysteryofsacubitrilvalsartanfromclinicaltrialtotherealworld AT yangxueli thehistoryandmysteryofsacubitrilvalsartanfromclinicaltrialtotherealworld AT hewang thehistoryandmysteryofsacubitrilvalsartanfromclinicaltrialtotherealworld AT weisun thehistoryandmysteryofsacubitrilvalsartanfromclinicaltrialtotherealworld AT binliu thehistoryandmysteryofsacubitrilvalsartanfromclinicaltrialtotherealworld AT mingsongzhang historyandmysteryofsacubitrilvalsartanfromclinicaltrialtotherealworld AT yifeizou historyandmysteryofsacubitrilvalsartanfromclinicaltrialtotherealworld AT yangxueli historyandmysteryofsacubitrilvalsartanfromclinicaltrialtotherealworld AT hewang historyandmysteryofsacubitrilvalsartanfromclinicaltrialtotherealworld AT weisun historyandmysteryofsacubitrilvalsartanfromclinicaltrialtotherealworld AT binliu historyandmysteryofsacubitrilvalsartanfromclinicaltrialtotherealworld |